

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton for 10 ml, 20 ml and 100 ml vial**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for dogs and cats  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam: 5 mg/ml,  
Ethanol (96%): 159.8 mg/ml.

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

10 ml  
20 ml  
100 ml

**5. TARGET SPECIES**

Dogs and cats

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTES OF ADMINISTRATION**

Dogs: Musculo-skeletal disorders: single subcutaneous injection.  
Post-operative pain: single intravenous or subcutaneous injection.

Cats: Post-operative pain: single subcutaneous injection.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

**9. SPECIAL WARNING, IF NECESSARY**

Do not use in pregnant or lactating animals.

**10. EXPIRY DATE**

EXP {month/year}  
Shelf-life of broached vial: 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton.

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER**

Vm 08749/5015

**17. MANUFACTURER'S BATCH NUMBER**

BN {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Label for 100 ml vials**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for cats and dogs  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam: 5 mg/ml,  
Ethanol (96%): 159.8 mg/ml.

**3. PHARMACEUTICAL FORM**

Solution for injection.

**4. PACKAGE SIZE**

100 ml

**5. TARGET SPECIES**

Dogs and cats

**6. INDICATIONS**

Read package leaflet before use.

**7. METHOD AND ROUTE OF ADMINISTRATION**

Dogs: Musculo-skeletal disorders: single subcutaneous injection.  
Post-operative pain: single intravenous or subcutaneous injection.

Cats: Post-operative pain: single subcutaneous injection.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Shelf life after first opening the immediate packaging: 28 days.

Once broached, use by...

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton.

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OF RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER**

Vm 08749/5015

**17. MANUFACTURER'S BATCH NUMBER**

BN {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

Label for 10 ml and 20 ml vials

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for dogs and cats  
Meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 5 mg/ml.

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 ml  
20 ml

**4. ROUTES OF ADMINISTRATION**

Dogs: IV or SC.  
Cats: SC.

**5. WITHDRAWAL PERIOD(S)**

Not applicable.

**6. BATCH NUMBER**

BN {number}

**7. EXPIRY DATE**

EXP {month/year}  
Once broached, use by...

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

## PACKAGE LEAFLET:

### Inflacam 5 mg/ml solution for injection for dogs and cats

#### **1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:  
Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway,  
Ireland

Manufacturers responsible for the batch release:  
Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway,  
Ireland

and

Eurovet Animal Health B.V.  
Handelsweg 25, 5531 AE Bladel,  
The Netherlands

and

Labiana Life Sciences, S.A., C/ Venus, 26, Pol. Ind. Can Parellada, Tarrasa, 08228  
Barcelona

#### **2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for dogs and cats  
Meloxicam

#### **3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One ml contains:

Meloxicam 5 mg,  
Ethanol (96%) 159.8 mg.  
Clear, yellow solution.



#### **4. INDICATIONS**

##### Dogs:

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

##### Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

#### **5. CONTRAINDICATIONS**

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

#### **6. ADVERSE REACTIONS**

Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure, have occasionally been reported. In very rare cases elevated liver enzymes have been reported.

In very rare cases, haemorrhagic diarrhoea, haematemesis, and gastrointestinal ulceration have been reported.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.

In very rare cases, anaphylactoid reactions may occur and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Dogs and cats.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Dosage for each species

Dogs: single administration of 0.2 mg meloxicam /kg body weight (i.e. 0.4 ml/10 kg).

Cats: single administration of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg).

### Method and routes of administration

#### Dogs:

Musculo-skeletal disorders: single subcutaneous injection.

Inflacam 1.5 mg/ml oral suspension for dogs or Inflacam 1 mg and 2.5 mg chewable tablets for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example, at the time of induction of anaesthesia.

#### Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example, at the time of induction of anaesthesia.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Particular care should be taken with regard to the accuracy of dosing.

Avoid introduction of contamination during use.

Maximum number of piercings is 42 for all presentations.

## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Keep the vial in the outer carton.

Do not use after the expiry date (EXP) stated on the carton and vial.

Shelf life after first opening the container: 28 days.

## **12. SPECIAL WARNINGS**

### Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

### Use during pregnancy and lactation:

Do not use in pregnant or lactating animals.

### Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anti-coagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects.

Inflacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g., aged animals), intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration.

When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

### Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose, symptomatic treatment should be initiated.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

**15. OTHER INFORMATION**

Carton box containing one colourless glass injection vial of 10 ml, 20 ml or 100ml, closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**United Kingdom (Northern Ireland)**

Virbac Ltd  
Suffolk  
IP30 9UP  
United Kingdom  
Tel: +44 (0)-1359 243243

*Gavin Hall*  
Approved: 27 November 2024